Endocrine System

Thyroid Disease—Radionuclide Diagnosis and Therapy

In 1941, the first patient was treated for thyroid cancer with radioiodine. Since then, radioiodine has proven invaluable in the assessment of thyroid disorders and treatment of thyroid cancer, Graves disease, and toxic thyroid nodules. Today, radioiodine I-123 and I-131 remain important diagnostic and therapeutic modalities, and the use of positron emission tomography (PET) iodine-124 is growing.

Thyroid Anatomy and Physiology

The thyroid gland lies in the anterior neck just inferior to the thyroid cartilage. It normally weighs 15 to 20 grams ( Fig. 8.1 ) and has two lobes connected by an isthmus that shows considerable anatomical variability. The pyramidal lobe, a remnant of the thyroglossal duct, is present in approximately two-thirds of patients, extending superiorly from the isthmus. Because of the thyroid’s embryological descent from pharyngeal pouches, ectopic tissue may be found anywhere from the foramen cecum at tongue base to the myocardium.

Fig. 8.1

Thyroid anatomy. The anatomical relationship of the thyroid to the trachea, thyroid and cricoid cartilages, and vascular structures.

The gland is made up of follicles of varying size. The epithelial follicular cells at the periphery of the follicle synthesize and secrete thyroid hormone into the lumen, which contains colloid, where the hormone is stored ( Fig. 8.2 ). After oral ingestion, iodine is reduced to iodide (I-) in the proximal small intestine, where more than 90% is absorbed within 60 minutes. After distributing in the blood as an extracellular ion, it exits by thyroid and gastric extraction, then urinary and intestinal excretion.

Fig. 8.2

Iodine metabolism. The thyroid follicular cell epithelium extracts (traps) iodide from the plasma via the sodium iodide symporter (thyroid pump) and organifies it. Iodide (I−) is converted to neutral iodine (I0), which is then incorporated into thyroglobulin-bound tyrosine molecules as monoiodotyrosine (MIT) or diiodotyrosine (DIT). Coupling of the iodotyrosines results in T 4 and T 3 hormone bound to the thyroglobulin, which is transported to and stored in the colloid, until T 4 and T 3 are released into the plasma by proteolytic enzymes. T 4 is converted to the more active T 3 peripherally.

A high-energy sodium-symporter membrane traps iodide and concentrates it intracellularly 25 to 500 times greater than plasma. Thyroid peroxidase at the follicular cell–colloid interface promptly organifies it. The iodide then binds to tyrosine residues on thyroglobulin. These monoiodinated and diiodinated tyrosines couple to form triiodothyronine (T 3 ) and thyroxine (T 4 ), which are stored in the colloid-filled follicular lumen (see Fig. 8.2 ). Trapping and uptake can be blocked competitively by monovalent anions (e.g., potassium perchlorate), and organification can be inhibited by drugs used for Graves therapy, such as propylthiouracil (PTU) and methimazole.

Serum thyroid-stimulating hormone (TSH) initiates iodide uptake, organification, and thyroglobulin hydrolysis, releasing thyroid hormone into the bloodstream. Thyroglobulin itself is not released, except during disease states (e.g., thyroiditis or thyroid cancer). The major hormone released by the thyroid is T4, which is transported to peripheral tissues by thyroid-binding proteins and converted to the more metabolically active T 3 . Because the normal gland contains a 1-month supply of hormone, drugs that block hormone synthesis do not become fully effective in controlling thyrotoxicosis until intrathyroidal stores are depleted.

TSH secretion is primarily adjusted through the thyroid–pituitary feedback mechanism ( Fig. 8.3 ). When serum thyroid hormone levels are above normal, as in hyperthyroidism, serum TSH is suppressed, but when they are low, as in hypothyroidism, serum TSH serum levels increase.

Fig. 8.3

Thyroid—pituitary feedback. The normal thyroid is under the control of thyroid-stimulating hormone (TSH). The hypothalamic production of thyroid-releasing hormone (TRH) and thus the pituitary release of TSH are increased with low circulating levels of T 4 and T 3 and decreased with high circulating levels of thyroid hormone.


Radioiodine-131 (I-131) and -123 (I-123)

Like the stable iodine (I-127) normally encountered in the diet, radioactive iodine isotopes, such as I-131 or I-123, are selectively trapped by the thyroid and incorporated into thyroid hormone. Given this ability to localize, they are excellent tools for evaluating thyroid physiology, emitting gamma rays that provide clinically relevant qualitative and quantitative information.

Radioiodine doses are usually supplied as a capsule for oral administration. Although liquid I-131 may be available, it is volatile and increases the risk of exposing those around the patient. In the proximal small bowel, more than 90% of ingested iodine is absorbed rapidly. It is detectable in the thyroid within minutes of oral ingestion, reaching the thyroid follicular lumen by 20 to 30 minutes. Thyroid uptake normally continues to increase occurs over 24 hours ( Fig. 8.4 ), although imaging can be done as soon as 4 hours. The delay between radioiodine administration and imaging is not due to slow accumulation but rather the time needed to clear relatively high background activity. Radioiodine uptake can also be seen in the salivary glands, stomach, and choroid plexus; however, it is not concentrated or retained there. Excretion is via the kidneys and gastrointestinal tract.

Fig. 8.4

Percent radioiodine uptake (%RAIU) after oral administration of I-123. In normal subjects the %RAIU increases progressively over 24 hours to values of 10% to 30% (gray area). With Graves disease, the %RAIU rises at a more rapid rate to higher levels, often 50% to 80% and greater (lower broken line). However, some patients with Graves have rapid iodine turnover within the thyroid manifested as early, rapid, high uptake at 4 to 12 hours but only mildly elevated or even normal uptake by 24 hours (top broken line).

I-131 undergoes beta-minus decay (β–), emitting a principal primary gamma photon of 364 keV with an 8.1-day physical half-life ( Table 8.1 ). These photons are not ideal for gamma camera imaging. Count detection sensitivity is poor; half of the photons penetrate the collimator septa (even with a high-energy collimator) and the 3/8-in. sodium iodine camera crystal without detection, thus resulting in image degradation. High-energy β-particles (0.606 megaelectron volt [MeV]) are also emitted, which cannot be imaged but are valuable for therapy. The high-energy gamma, β-emissions, and long physical half-life result in a relatively high radiation dose to the thyroid (see the Appendix). Therefore, the dose for uptake is limited to 10 to 20 μCi. Even after thyroidectomy, doses are typically limited to 2 to 3 mCi (74 MBq) for thyroid cancer imaging because the β-emission could cause stunning in the residual cells, preventing uptake for effective therapy or future imaging. In the past, 30 to 50 μCi (1110–1850 MBq) of I-131 was sometimes used to determine whether an anterior mediastinal mass was due to a goiter. I-123 has replaced I-131 for this purpose.

Table 8.1

Physical Characteristics of Thyroid Radiopharmaceuticals

Characteristics Tc-99m I-123 I-131 I-124
Mode of decay Isometric transition Electron capture Beta minus Positron
Physical half-life (T ½ ) 6 hours 13.2 hours 8.1 days 110 min
Photon energy 140 keV 159 keV 364 keV 511 keV
Abundance a 89% 83% 81% 100%
Beta emissions None None 606 keV None

a Abundance is the percent likelihood that a photon emission will occur with each radioactive decay.

I-123 decays by electron capture (13.2-hour half-life), and the principal emission is a 159-keV gamma photon (83.4% abundance), well suited for gamma camera imaging (see Table 8.1 ). There are some higher-energy emissions in low abundance, 440 to 625 keV (2.4%) and 625 to 784 (0.15%), making a medium-energy collimator preferable, although low-energy collimators are acceptable. Cyclotron production today results in I-123 that is 99.9% pure and no longer contaminated by long-lived isotopes (e.g., I-124, I-125). Given this and the lack of β-emissions, the radiation dose to the patient is roughly 100 times less than I-131 (10 rads/mCi) compared with 1000 rad/mCi. The standard uptake dose is 100 μCi (3.7 MBq) and 200 to 400 μCi (7.4 MBq) for routine thyroid scans. Higher doses can also be used in cancer imaging because I-123 does not cause stunning.

I-124 is a positron emitter that has been used as an alternative to I-123 or I-131 for thyroid cancer imaging, largely in an experimental capacity. It is cyclotron produced, decays by electron capture (75%) and positron decay (26%), and has a half-life of 4.18 days (see Table 8.1 ). Studies suggest it is superior to I-123 or I-131 for the detection of thyroid cancer metastases, and it has a potential role for thyroid cancer dosimetry before therapy. However, radiation dosimetry is relatively high (see Table 8.1 ).

Tc-99m pertechnetate is produced from a Mo-99/Tc99m generator, making it inexpensive and readily available, unlike the costlier I-123, which must often be ordered a day in advance. Because it is taken up by the same mechanism as iodine, Tc-99m pertechnetate can be used for thyroid assessment. The 140-keV photopeak (89% abundance) and lack of high-energy emissions are optimal for gamma camera imaging (see Table 8.1 ). In contrast to oral administration of radioiodine, Tc-99m pertechnetate is administered intravenously and rapidly taken up by the thyroid. However, it is not organified or retained in the thyroid, and imaging must be performed early at peak uptake time, 15 to 30 minutes after injection. The lack of particulate emissions and short 6-hour half-life result in a low radiation dose to the thyroid, far less than I-131 or I-123 (see the Appendix). Thus, the administered activity of Tc-99m pertechnetate can be much higher than that for I-123, usually 3 to 5 mCi (111–185 MBq), and the large photon flux results in high-quality images.

Special Considerations and Precautions

I-123 is the agent of choice for most adult thyroid imaging. Tc-99m pertechnetate may be preferred in children because of its lower radiation dosimetry and high count rate. However, because it is not organified, it is not recommended for nodule evaluation, and the rarely attempted Tc-99m pertechnetate uptake calculation is more difficult and less reliable.

For thyroid cancer imaging, the long half-life of I-131 is an important advantage over Tc-99m pertechnetate. Diagnostic I-131 scans are routinely acquired 48 hours after administration and 7 days posttherapy. The result is a high target-to-background ratio due to the time allowed for background clearance, resulting in good detectability of thyroid cancer metastases. Even for this diagnostic indication, I-123 is replacing I-131 because it permits earlier patient imaging at 24 hours, better image quality, and similar accuracy, and I-123 does not cause thyroid cell “stunning,” a situation where the cells are damaged by the emitted β, preventing future radioiodine uptake for imaging or therapy. These same high-energy I-131 β-emissions result in effective therapy not only for thyroid cancer but also for Graves disease and toxic nodules.

Uptake Inhibitors

A patient history, including food, drug, and prior imaging, should be obtained before thyroid uptake and imaging studies or radioiodine therapy. Thyroid replacement medications prevent imaging radiotracer uptake, as will thyroid-blocking medications. Exogenous iodine suppresses uptake and may preclude successful imaging or accurate uptake measurements. As little as 1 mg of stable iodine can cause a marked reduction in uptake; 10 mg can effectively block the gland.

Iodinated oral and intravenous radiographic contrast is a common source of iodine that interferes with thyroid studies. Given the high amount of iodine present in intravenous contrast, even water soluble, radionuclide diagnostic and therapeutic studies should be delayed for approximately 4 weeks following contrast administration.

The iodine normally found in foods and medications can also interfere with radionuclide thyroid studies ( Table 8.2 ). Greater amounts of iodine in the normal diet over the years in the form of iodized salt has resulted in lower normal values for the percent radioiodine uptake (%RAIU). Chronic renal failure impairs iodide clearance, expands the iodide pool, and lowers the %RAIU. Hypothyroidism reduces the glomerular filtration rate and slows urinary clearance of radioiodine from the body; hyperthyroidism increases the clearance rate.

Table 8.2

Drugs, Foods, and Radiographic Contrast Agents That Decrease or Increase the Percent Radioactive Iodine Thyroid Uptake

Decrease Uptake Duration of Effect
Thyroid hormones

  • Thyroxine (T 4 )

  • 4–6 weeks

  • Triiodothyronine (T 3 )

2 weeks
Excess iodine (expanded iodine pool)

  • Potassium iodide

2–4 weeks

  • Mineral supplements, cough medicines, vitamins

2–4 weeks

  • Iodine food supplements

2–4 weeks

  • Iodinated drugs (e.g., amiodarone)


  • Iodinated skin ointments

2–4 weeks
Congestive heart failure
Renal failure

  • Radiographic contrast media

  • Water-soluble intravascular media

  • 3–4 weeks

  • Fat-soluble media (lymphography)

Months to years

  • Non–iodine-containing drugs

  • Adrenocorticotropic hormone, adrenal steroids

  • Variable

  • Monovalent anions (perchlorate)

  • Variable

  • Penicillin

  • Variable

  • Antithyroid drugs

  • Propylthiouracil (PTU)

  • 3–5 days

  • Methimazole (Tapazole)

5–7 days

  • Goitrogenic foods

  • Cabbage, turnips

  • Prior radiation to neck

Increase uptake

  • Iodine deficiency

  • Pregnancy

  • Rebound after therapy withdrawal

  • Antithyroid drugs

  • Lithium

Iodine Allergy

The amount of iodine in a radioactive uptake or even a therapy dose is subpharmacologic and has not been associated with allergic reactions, even in patients with a documented iodine allergy.

Pregnancy and Lactation

The fetal thyroid begins to concentrate radioiodine by 10 to 12 weeks of gestation. Thus, significant exposure of the fetal thyroid can occur after therapeutic doses given to the mother, resulting in fetal hypothyroidism. A serum pregnancy test is mandatory before treating a female patient with I-131. Radioiodine is excreted in human breast milk. Because of the long half-life of I-131, nursing should be discontinued after diagnostic or therapeutic studies and not resumed. Breastfeeding may resume 48 hours after administration of I-123 and 24 hours after Tc-99m pertechnetate. According to the Nuclear Regulatory Commission (NRC), patients receiving I-131 for therapy or imaging should receive written as well as verbal radiation safety instructions if they are breastfeeding in addition to the routine instructions and normally required written directives.

Thyroid Uptake (%RAIU)

Thyroid uptake measurements for benign disease are acquired using a nonimaging gamma scintillation probe detector ( Figs. 8.5 and 8.6 ). The %RAIU can be determined with either I-131 or I-123 ( Box 8.1 ). Clinical indications are limited ( Table 8.3 ). It is most commonly used in the calculation of an I-131 therapy dose or to diagnose the cause of thyrotoxicosis, most commonly to differentiate Graves disease from subacute thyroiditis. Thyroid uptake values in other diseases are listed in Box 8.2 . The %RAIU is increased in Graves but suppressed in subacute thyroiditis.

Fig. 8.5

Thyroid uptake probe counting I-123 capsule in neck phantom. The neck phantom is solid Lucite plastic, except for the cylinder-like defect in which the capsule is placed for counting. The nonimaging gamma detector is placed at a standard distance of 30 cm from the neck phantom and acquires emitted counts for 1 minute.

Fig. 8.6

Thyroid uptake probe is positioned 30 cm from the patient’s neck, where it acquires counts from the patient’s neck/thyroid for 1 minute. Background counts are also acquired, usually in the thigh region.

Box 8.1

Calculation of Radioactive Iodine and Tc-99m Uptakes

Percent Radioiodine Uptake (%RAIU)

  • 1.

    Preliminary measurements

    • Place dose capsule in neck phantom and count for 1 minute.

    • Count patient’s neck and thigh (background) for 1 minute.

  • 2.

    Administer oral dose capsule.

  • 3.

    Uptake measurement at 4 to 6 hours and 24 hours:

    • Count patient’s neck for 1 minute.

    • Count patient’s thigh for 1 minute.

  • 4.


<SPAN role=presentation tabIndex=0 id=MathJax-Element-1-Frame class=MathJax style="POSITION: relative" data-mathml='%RAIU=Neck(backgroundcorrected)counts/minDosecapsule(decaycorrectedbackgroundcorrected)counts/min×100′>%RAIU=Neck(backgroundcorrected)counts/minDosecapsule(decaycorrectedbackgroundcorrected)counts/min×100%RAIU=Neck(backgroundcorrected)counts/minDosecapsule(decaycorrectedbackgroundcorrected)counts/min×100

Tc-99m Pertechnetate %Uptake

  • Before and after injection, the syringe is imaged to obtain counts (preinjection counts – postinjection counts = administered counts).

  • Scan regions of interest (ROIs) are drawn for thyroid, thyroid background.

  • Areas of interest are normalized for pixel size, and thyroid and syringe counts are normalized for time of acquisition.

  • Normal values are 0.3% to 4.5%.

Table 8.3

Clinical Indications for Thyroid Scan and %Thyroid Uptake

Thyroid Scan %Thyroid uptake
Functional status (cold, hot) of thyroid nodule Differential diagnosis of thyrotoxicosis
Detection of ectopic thyroid tissue (e.g., lingual thyroid) Calculate Graves I-131 therapy dose
Differential diagnosis of mediastinal masses (substernal goiter) with I-123 Whole-body thyroid cancer scans pretherapy, posttherapy, and follow-up—to quantify residual or recurrent disease
Thyroid cancer whole-body scan:

  • Before therapy—find distant disease

  • Posttherapy—find additional disease

Follow-up—determine therapeutic effectiveness, evaluate for recurrence

Box 8.2

Differential Diagnosis of Thyrotoxicosis: Increased or Decreased %RAIU

Increased Uptake

  • Graves disease

  • Toxic nodular goiter

  • Hashitoxicosis

  • Hydatidiform mole, trophoblastic tumors, choriocarcinoma

  • Metastatic thyroid cancer

Decreased Uptake

  • Subacute thyroiditis

    • Granulomatous thyroiditis (de Quervain)

    • Silent thyroiditis

    • Postpartum thyroiditis

    • Iodine-induced thyrotoxicosis (Jod–Basedow)

    • Amiodarone-induced thyrotoxicosis

    • Thyrotoxicosis factitia

    • Struma ovarii (decreased in thyroid, increased in ovarian tumor)

Medications that interfere with the radioiodine uptake should be discontinued before the study, with the length of time based on their half-lives (see Table 8.2 ). Patients should have nothing by mouth for 4 hours before radioiodine ingestion to ensure good absorption. I-123 and I-131 are usually administered in capsule form.

If a scan is not needed, 5 to 10 μCi I-131 or 50 μCi I-123 is adequate for a %RAIU because of the gamma probe’s high detection sensitivity. If a scan is ordered, Tc-99m pertechnetate can be utilized following the I-131 uptake. Both the scan and uptake can be performed with the I-123 scan dose (200–400 μCi). The %RAIU is best acquired at 4 and 24 hours after ingestion, although some acquire it at only one time period. The 24-hour uptake is the standard for I-131 therapy dose calculation.

Methodology for %RAIU

The nonimaging gamma scintillation probe detector used for thyroid uptake studies has a 2-cm-thick by 2-cm-diameter sodium iodine crystal with an open, single-hole lead collimator coupled to a photomultiplier tube and electronics. Room background activity is determined. The radioiodine capsule with known calibrated activity is placed in a Lucite neck phantom (see Fig. 8.5 ). Counts are obtained with the detector placed at a standardized distance of 30 cm. The radioiodine dose is then administered to the patient. At 4 and/or 24 hours, the probe is placed 30 cm from the anterior surface of the patient’s neck (see Fig. 8.6 ). Counts are obtained for 1 minute. The patient’s thigh is counted for a similar time to correct for background. The %RAIU is calculated according to the following formula:

<SPAN role=presentation tabIndex=0 id=MathJax-Element-2-Frame class=MathJax style="POSITION: relative" data-mathml='%RAIU=Neckcounts/min∗Administreddosecapsulecounts/min∗correctedfordecayandbackground×100′>%RAIU=Neckcounts/minAdministreddosecapsulecounts/mincorrectedfordecayandbackground×100%RAIU=Neckcounts/min∗Administreddosecapsulecounts/min∗correctedfordecayandbackground×100

The normal range for the %RAIU is approximately 4% to 15% at 4 to 6 hours and 10% to 30% at 24 hours. The early uptake informs that the %RAIU is elevated or suppressed. Some centers extrapolate from 4-hour uptake to estimate the 24-hour uptake for I-131 therapy dose planning. A problem with this approach is that some hyperthyroid patients have rapid thyroid iodine turnover. These patients may show an elevated 4- to 6-hour %RAIU but a lower value at 24 hours, thus underestimating the therapy dose needed (see Fig. 8.4 ). Patients with very high 4-hour uptakes can be brought back at 24 hours to ensure correct dosing, but having both time points is always optimal. The significance of uptake values must be determined by considering the entire clinical picture. Causes for various uptake values are outlined in Table 8.4 .

Table 8.4

Relationship of %Radioiodine Thyroid Uptake to Thyroid Function

%Radioiodine Thyroid Uptake
Thyroid Function Increased Normal Decreased
Thyrotoxicosis Graves disease
Antithyroid drugs
Contrast, high iodine exposure
Subacute thyroiditis, thyrotoxic phase
Thyrotoxicosis factitia
Antithyroid drugs
Struma ovarii
Euthyroid Rebound after antithyroid drug withdrawal
Recovery from subacute thyroiditis
Compensated dyshormonogenesis
Decompensated dyshormonogenesis
Hypothyroid Decompensated dyshormonogenesis
Hashimoto disease
Hashimoto disease
After I-131 therapy
Subacute thyroiditis, recovery phase decompensated dyshormonogenesis
Hypothyroidism: primary or secondary

A Tc-99m pertechnetate percentage uptake is not commonly performed. Advantages are that peak uptake occurs at 20 to 30 minutes compared with 4 and 24 hours for radioiodine. Disadvantages are a considerably lower accuracy than %RAIU, often a lack of commercial software available for calculation, and a 24-hour uptake is not possible because it is not organified. The methodology is described in Box 8.1 .

Thyroid Scan

Iodine-123 is administered orally, and the scan is acquired 4 hours later. Imaging at 24 hours is possible; however, the low count rate at that time requires longer acquisition, increasing the likelihood of patient motion and image degradation. Four-hour images have superior image quality. Tc-99m pertechnetate is administered intravenously, and scan acquisition begins 20 minutes later. Detailed protocols are described for both in Box 8.3 .

Box 8.3

Thyroid Imaging With Iodine-123 and Tc-99m Pertechnetate: Protocol Summary

Patient Preparation

  • Discontinue medications that interfere with thyroid uptake (see Table 8.2 ).

  • Nothing by mouth for 4 hours before study.


  • Iodine I-123, 200 to 400 μCi (3.7–14.8 MBq), orally in capsule form (or)

  • Tc-99m pertechnetate, 3 to 5 mCi (111–185 MBq), intravenously

Time of Imaging

  • Iodine I-123, 4 hours after oral dose administration

  • Tc-99m pertechnetate, 20 minutes after injection

Imaging Procedure

  • Gamma camera with pinhole collimator

  • Energy window:

    • Tc-99m pertechnetate: 15% to 20% energy window centered at 140 keV

    • I-123: 20% window centered at 159 keV

  • Position the supine patient with the chin up and neck extended.

  • Acquire initial anterior view for 100,000 counts or 5 minutes with collimator placed to include right side and suprasternal notch markers.

  • Place the collimator closer so that the thyroid fills about approximately two-thirds of the field of view.

  • Acquire anterior, left anterior oblique, and right anterior oblique images for equal time compared with anterior view.

Only gold members can continue reading. Log In or Register to continue

Aug 11, 2020 | Posted by in NUCLEAR MEDICINE | Comments Off on Endocrine System
Premium Wordpress Themes by UFO Themes